News

October 30, 2015October 30, 2015

Biomarkers in Rheumatoid Arthritis Seen as Key in Early Diagnosis, Proper Care

News

The promise that the field of biomarkers hold for earlier diagnosis and hence superior treatment of systemic autoimmune diseases, in which rheumatoid arthritis is included, were the focus of a recent review in ... Read more

October 29, 2015October 29, 2015

Moderate-to-Severe Rheumatoid Arthritis Patients May Benefit from Olokizumab

News

A new study entitled “Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment” will be presented during the 2015 American College of ... Read more

October 23, 2015October 26, 2015

Baricitinib Demonstrated Superior Activity in Patients with Rheumatoid Arthritis

News

Lilly and Incyte recently announced results from their fourth Phase III study (RA-BEAM) on baricitinib in patients with active rheumatoid arthritis (RA). Historically, these clinical trials passed through several stages, which started as first ... Read more

October 21, 2015October 21, 2015

Cytokine Levels Seen to Impair Inflammation Progression in Rheumatoid Arthritis

News

In a new study entitled “Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis” researchers discovered that the cytokine interleukin-27 (IL-27) inhibits the formation of ectopic lymphoid-like structures (ELSs) ... Read more

October 14, 2015October 15, 2015

Study Finds Inflammation Mechanisms In Rheumatoid Arthritis Patients

News

In a newly published paper in Mediators of Inflammation journal entitled “Differences of IL-1β Receptors Expression by Immunocompetent Cells Subsets in Rheumatoid Arthritis“, scientists reported new insights into the mechanisms of ... Read more

October 12, 2015October 12, 2015

IL-27 Is A Biomarker For RA Sub-Type Identification

News

Immunology researchers from the University of Cardiff have identified a mechanism involving interleukin-27 in the inflammatory pathway of rheumatoid arthritis associated with lymphoid tissue formation. The study, funded by Arthritis ... Read more

October 7, 2015October 7, 2015

AbbVie To Proceed With Phase III Studies For ABT-494 In Rheumatoid Arthritis

News

Global biopharmaceutical company, AbbVie, recently revealed plans to further develop its lead selective JAK1 inhibitor product candidate, ABT-494 in a Phase III clinical study on rheumatoid arthritis (RA). This step ... Read more

October 2, 2015October 5, 2015

AbbVie Announces ABT-494 Met Primary Endpoint in Two Phase II Studies In Severe Rheumatoid Arthritis Patients

News

AbbVie recently announced positive data from two Phase II studies that evaluated the company’s selective JAK1 inhibitor, called ABT-494, in patients with rheumatoid arthritis (RA) with an inadequate response to either methotrexate or ... Read more

September 30, 2015October 1, 2015

RuiYi Doses First Human in Gerilimzumab Study for Rheumatoid Arthritis

News

RuiYi, Inc., a biopharmaceutical company focused on discovering and developing novel antibody-based therapeutics, recently announced it has dosed the first human subject in the study of lead product candidate, Gerilimzumab, a ... Read more

September 23, 2015September 23, 2015

Depression and Anxiety Predict Treatment Response and Health Outcomes in Rheumatoid Arthritis

News

Depression and anxiety are highly prevalent in rheumatoid arthritis (RA) patients, with a recent meta-analysis reporting a 16.8% prevalence of depression, diagnosed via clinical interview. There is evidence to suggest a ... Read more